6505--Oxybutynin CL SA Tablets

The solicitation requires offerors to submit a compliant small‑business subcontracting plan in accordance with FAR 52.219‑9 for any contract valued over $750,000. Offerors must provide either an approved commercial plan (including all indirect costs) or a new individual plan that details the method for allocating indirect costs to small‑business, veteran‑owned, service‑disabled veteran‑owned, HUBZone, small‑disadvantaged, and women‑owned concerns. The plan must set dollar and percentage goals—rounded to one decimal place—for each of these categories (SB, VO, SDVO, SDB, WO, HUB) for the base period and any option years, and must be accompanied by the required FAR representations (52.209‑7, 52.219‑1, 52.204‑24, 52.225‑6, 52.212‑3) completed online via SAM.gov. The contract will flow down FAR 52.219‑8 to all subcontracts, and an equitable‑opportunity statement and program‑administrator contact information are required. In addition, all proposed drug products/NDCs must already be listed on the offeror’s FSS contract or interim agreement with an established Permanent FCP by the offer deadline; non‑compliant offers will be rejected. Offerors must also submit quarterly sales reports and remit cost‑recovery fees as specified. The solicitation is set aside for multiple small‑business categories (including HUBZone, SDVOSB, WOSB/EDWOSB) and includes detailed usage estimates for several oxybutynin tablet strengths, which must be reflected in the pricing and subcontracting strategy.

Notice ID

f23a6a1e61f0478f8c903974f8910636

Solicitation Number

36E79725R0062

NAICS Code

325412

Classification Code

6505